At Charles River, we combine deep expertise and extensive capabilities to create innovative, flexible and efficient solutions to advance neurological research and drug discovery. Our scientists continue to establish the most relevant in vitro and in vivo disease models to target acute and chronic neurological diseases. Our team is uniquely positioned to partner with clients, accelerating drug development from early discovery to the delivery of exciting new CNS therapies.
We offer disease specific models and assay systems to validate therapeutic modalities, including small molecules, biologics and gene therapies for efficacy and safety. Our portfolio includes validated models with clinically relevant endpoints for established and emerging disease conditions, including: